Open AccessBenzodiazepine and zolpidem prescriptions during autologous stem cell transplantation
Author(s) -
Banerjee Rahul,
Lazar Ann A.,
Dunn Lisa,
Knoche Jennifer,
Lo Mimi,
Arora Shagun,
Wong Sandy W.,
Wolf Jeffrey L.,
Martin Thomas G.,
Dhruva Anand,
Shah Nina
Publication year - 2021
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.148
Subject(s) - zolpidem , autologous stem cell transplantation , medicine , multiple myeloma , medical prescription , anxiety , benzodiazepine , insomnia , oncology , transplantation , psychiatry , pharmacology , receptor
Multiple myeloma patients undergoing autologous stem cell transplantation (ASCT) may receive benzodiazepine or zolpidem‐class (B/Z) medications despite their risks in older patients. Of 205 myeloma patients (36% aged 65+) who underwent ASCT at our institution between 2017 and 2018, we found that B/Z prescription rates for anxiety/insomnia rose significantly from 26% before ASCT to 38% at discharge and 39% at Day +100. B/Z initiation while hospitalized was a strong predictor of B/Z persistence at Day +100. Our findings highlight the role of these potentially inappropriate medications during hospitalizations for ASCT, a period where nonpharmacologic strategies for managing anxiety/insomnia may be feasible.